{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:45:25Z","timestamp":1789998325103,"version":"4.0.1"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"1102","license":[{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:p>Nasopharyngeal cancer (NPC) is notable for its wide geographic variation, with incidences as high as 30 in 100,000 in endemic regions but &amp;lt; 1 in 100,000 worldwide. This review aims to identify areas where there could be differences in prognosis, management or outcomes among countries with high or low incidence of NPC. The incidence has generally declined both in endemic and non-endemic regions throughout the years, which may be attributed to the decrease in exposure to risk factors such as early exposure to salted fish and smoking. Ethnicity has an impact both on incidence and prognosis, with Southeast Asians having the highest incidence but also better survival. Concurrent chemoradiotherapy, with or without adjuvant and\/or induction chemotherapy, is the standard of care for locoregionally advanced disease, as reflected in clinical practice guidelines. Despite improvements in management, a proportion of patients relapse. Salvage treatment is associated with significant morbidity due to the critical location of the nasopharynx and the toxicities of initial therapy. Clinical expertise is paramount, but is easier to attain in endemic regions and high volume centers where enrollment of patients in clinical trials is more feasible. Collaboration between low and high incidence countries and between low and high volume facilities is key to improving NPC prognosis worldwide.<\/jats:p>","DOI":"10.1259\/bjr.20190068","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T17:57:51Z","timestamp":1559325471000},"source":"Crossref","is-referenced-by-count":21,"title":["Does East meet West? Towards a unified vision of the management of Nasopharyngeal carcinoma"],"prefix":"10.1093","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3718","authenticated-orcid":false,"given":"Elaine Johanna","family":"Limkin","sequence":"first","affiliation":[{"name":"Gustave Roussy, Department of Radiotherapy, Universit\u00e9 Paris-Saclay, F-94805 , Villejuif , France"},{"name":"Department of Radiation Oncology, 1634, Saint Luke\u2019s Medical Center Global City , Taguig , Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blanchard","sequence":"additional","affiliation":[{"name":"Gustave Roussy, Department of Radiotherapy, Universit\u00e9 Paris-Saclay, F-94805 , Villejuif , France"},{"name":"INSERM U1018, CESP, Universit\u00e9 Paris-Sud, Universit\u00e9 Paris-Saclay, F-94805 , Villejuif , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,31]]},"reference":[{"key":"2024050214503115300_b1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"2024050214503115300_b2","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1055-9965.EPI-06-0353","article-title":"The enigmatic epidemiology of nasopharyngeal carcinoma","volume":"15","author":"Chang","year":"2006","journal-title":"Cancer Epidemiology Biomarkers & Prevention"},{"key":"2024050214503115300_b3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12105-017-0787-0","article-title":"Update from the 4th edition of the World Health organization classification of head and neck tumours: nasopharynx","volume":"11","author":"Stelow","year":"2017","journal-title":"Head Neck Pathol"},{"key":"2024050214503115300_b4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0196-0709(95)90040-3","article-title":"Prognostic significance of keratinization in nasopharyngeal carcinoma","volume":"16","author":"Reddy","year":"1995","journal-title":"Am J Otolaryngol"},{"key":"2024050214503115300_b5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/(SICI)1097-0142(19980801)83:3<582::AID-CNCR29>3.0.CO;2-R","article-title":"The National Cancer data base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma","volume":"83","author":"Marks","year":"1998","journal-title":"Cancer"},{"key":"2024050214503115300_b6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40880-016-0103-5","article-title":"A new prognostic histopathologic classification of nasopharyngeal carcinoma","volume":"35","author":"Wang","year":"2016","journal-title":"Chin J Cancer"},{"key":"2024050214503115300_b7","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"2024050214503115300_b8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/ijc.10894","article-title":"Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): an encouraging reduction in both incidence and mortality","volume":"103","author":"Lee","year":"2003","journal-title":"Int J Cancer"},{"key":"2024050214503115300_b9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.canlet.2016.01.040","article-title":"Global trends in incidence and mortality of nasopharyngeal carcinoma","volume":"374","author":"Tang","year":"2016","journal-title":"Cancer Lett"},{"key":"2024050214503115300_b10","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ijc.30525","article-title":"Risk of nasopharyngeal carcinoma penetrates across immigrant generations: a migrant cohort study of 2.3 million Jewish Israeli adolescents","volume":"140","author":"Rottenberg","year":"2017","journal-title":"Int J Cancer"},{"key":"2024050214503115300_b11","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1002\/ijc.25287","article-title":"Nasopharyngeal and hypopharyngeal carcinoma risk among immigrants in Sweden","volume":"127","author":"Mousavi","year":"2010","journal-title":"Int J Cancer"},{"key":"2024050214503115300_b12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/1874357901509010007","article-title":"Epstein- Barr virus: clinical and epidemiological Revisits and genetic basis of oncogenesis","volume":"9","author":"Ali","year":"2015","journal-title":"Open Virol J"},{"key":"2024050214503115300_b13","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/346470a0","article-title":"Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region","volume":"346","author":"Lu","year":"1990","journal-title":"Nature"},{"key":"2024050214503115300_b14","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2174\/156652409788970698","article-title":"HLA associations with nasopharyngeal carcinoma","volume":"9","author":"Li","year":"2009","journal-title":"Curr Mol Med"},{"key":"2024050214503115300_b15","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/jnci\/89.16.1207","article-title":"CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan","volume":"89","author":"Hildesheim","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"2024050214503115300_b16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-1-4","article-title":"Cytochrome P450 2E1 polymorphism and nasopharyngeal carcinoma development in Thailand: a correlative study","volume":"1","author":"Kongruttanachok","year":"2001","journal-title":"BMC Cancer"},{"key":"2024050214503115300_b17","first-page":"1100","article-title":"Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1","volume":"12","author":"Cho","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2024050214503115300_b18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5732\/cjc.010.10377","article-title":"The prevalence and prevention of nasopharyngeal carcinoma in China","volume":"30","author":"Cao","year":"2011","journal-title":"Chin J Cancer"},{"key":"2024050214503115300_b19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/bjc.1994.92","article-title":"Environmental and dietary risk factors for nasopharyngeal carcinoma: a case-control study in Zangwu County, Guangxi, China","volume":"69","author":"Zheng","year":"1994","journal-title":"Br J Cancer"},{"key":"2024050214503115300_b20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10654-007-9148-8","article-title":"Secular trends of nasopharyngeal carcinoma incidence in Singapore, Hong Kong and Los Angeles Chinese populations, 1973-1997","volume":"22","author":"Luo","year":"2007","journal-title":"Eur J Epidemiol"},{"key":"2024050214503115300_b21","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1017\/S0022215109005623","article-title":"Incidence of nasopharyngeal carcinoma in Chinese immigrants, compared with Chinese in China and South East Asia: review","volume":"123","author":"Yu","year":"2009","journal-title":"J Laryngol Otol"},{"key":"2024050214503115300_b22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/aje\/kws479","article-title":"Quantitative association of tobacco smoking with the risk of nasopharyngeal carcinoma: a comprehensive meta-analysis of studies conducted between 1979 and 2011","volume":"178","author":"Xue","year":"2013","journal-title":"Am J Epidemiol"},{"key":"2024050214503115300_b23","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.15585\/mmwr.mm6444a2","article-title":"Current cigarette smoking among adults - United States, 2005-2014","volume":"64","author":"Jamal","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024050214503115300_b24","first-page":"587","article-title":"Nasopharyngeal cancer in a low-risk population: defining risk factors by histological type","volume":"5","author":"Vaughan","year":"1996","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2024050214503115300_b25","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/0194599816672625","article-title":"Racial and ethnic disparities in nasopharyngeal cancer survival in the United States","volume":"156","author":"Patel","year":"2017","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2024050214503115300_b26","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.canep.2013.08.008","article-title":"Racial differences in nasopharyngeal carcinoma in the United States","volume":"37","author":"Wang","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"2024050214503115300_b27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/COC.0000000000000091","article-title":"Asian versus non-Asian outcomes in nasopharyngeal carcinoma: a North American population-based analysis","volume":"39","author":"Hamilton","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"2024050214503115300_b28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/coa.13225","article-title":"Survival differences in nasopharyngeal carcinoma among racial and ethnic minority groups in the United States: a retrospective cohort study","volume":"44","author":"Challapalli","year":"2019","journal-title":"Clin Otolaryngol"},{"key":"2024050214503115300_b29","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ijrobp.2013.11.246","article-title":"Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis","volume":"88","author":"Stenmark","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050214503115300_b30","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"JCO"},{"key":"2024050214503115300_b31","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2002.08.149","article-title":"Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial","volume":"20","author":"Chan","year":"2002","journal-title":"JCO"},{"key":"2024050214503115300_b32","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.1200\/JCO.2005.16.790","article-title":"Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer\/International Union Against cancer stage III and IV nasopharyngeal cancer of the endemic variety","volume":"23","author":"Wee","year":"2005","journal-title":"J Clin Oncol"},{"key":"2024050214503115300_b33","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/cncr.28049","article-title":"Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVb nasopharyngeal carcinoma from endemic regions of China","volume":"119","author":"Chen","year":"2013","journal-title":"Cancer"},{"key":"2024050214503115300_b34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","article-title":"Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis","volume":"16","author":"Blanchard","year":"2015","journal-title":"Lancet Oncol"},{"key":"2024050214503115300_b35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1470-2045(11)70320-5","article-title":"Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial","volume":"13","author":"Chen","year":"2012","journal-title":"Lancet Oncol"},{"key":"2024050214503115300_b36","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"issue":"S2","key":"2024050214503115300_b37","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1017\/S0022215116000517","article-title":"Nasopharyngeal carcinoma: United Kingdom National multidisciplinary guidelines","volume":"130","author":"Simo","year":"2016","journal-title":"J Laryngol Otol"},{"key":"2024050214503115300_b38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12094-017-1777-0","article-title":"SEOM clinical guideline in nasopharynx cancer (2017","volume":"20","author":"Pastor","year":"2018","journal-title":"Clin Transl Oncol"},{"issue":"Suppl 7","key":"2024050214503115300_b39","doi-asserted-by":"crossref","first-page":"vii83","DOI":"10.1093\/annonc\/mds266","article-title":"Nasopharyngeal cancer: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23 Suppl 7","author":"Chan","year":"2012","journal-title":"Ann Oncol"},{"key":"2024050214503115300_b40","volume-title":"{Malaysia Health Technology Assessment Section (MaHTAS) Medical Development Division, Ministry of Health Malaysia}","author":"Clinical Practice Guidelines Management of Nasopharyngeal Carcinoma [Internet]","year":"2016"},{"key":"2024050214503115300_b41","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.oraloncology.2013.05.010","article-title":"Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines","volume":"49","author":"D'cruz","year":"2013","journal-title":"Oral Oncol"},{"key":"2024050214503115300_b42","unstructured":"Princess Margaret Cancer Center Clinical Practice Guidelines\n          \n.\nHead and Neck (Nasopharynx) [Internet]\n.\n2015\n\u00a0Sep\n. Available from:\nhttps:\/\/www.uhn.ca\/PrincessMargaret\/Health.\/CPG_HeadNeck_Nasopharynx.pdf"},{"key":"2024050214503115300_b43","unstructured":"Nasopharyngeal Cancer Treatment Clinical Practice Guideline HN 003\n          \n.\n2013 Dec;\nAvailable from:\nwww.albertahealthservices.ca"},{"key":"2024050214503115300_b44","volume-title":"Members of the Head and Neck Cancer Disease Site Group. Chemotherapy with Radiotherapy for Nasopharyngeal Cancer. Toronto (ON): Cancer Care Ontario Program in Evidence-based Care Practice Guideline","author":"Thephamongkhol","year":"2013;"},{"key":"2024050214503115300_b45","unstructured":"Saskatchewan Cancer Agency Nasopharyngeal Cancer Guidelines [Internet]\n          \n.\n2015 May.\nAvailable from:\nwww.saskcancer.ca\/Head%20and%20Neck%20CPGs%2005-15"},{"key":"2024050214503115300_b46","unstructured":"National Comprehensive Cancer Network\n          \n.\nHead and Neck Cancers. Version 2.2018 [Internet]\n. [\ncited 2019 Mar 1\n]. Available from:\nhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf"},{"key":"2024050214503115300_b47","volume-title":"Nasopharyngeal Cancer Treatment (Adult) (PDQ\u00ae)\u2013Health Professional Version [Internet]","author":"National Cancer Institute","year":"2019"},{"key":"2024050214503115300_b48","doi-asserted-by":"crossref","first-page":"336","DOI":"10.6004\/jnccn.2017.0033","article-title":"Critical evaluation of the quality and recommendations of clinical practice guidelines for nasopharyngeal carcinoma","volume":"15","author":"Chen","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"2024050214503115300_b49","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ijrobp.2006.06.013","article-title":"Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial","volume":"66","author":"Pow","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050214503115300_b50","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1200\/JCO.2007.11.5501","article-title":"Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients","volume":"25","author":"Kam","year":"2007","journal-title":"J Clin Oncol"},{"key":"2024050214503115300_b51","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0360-3016(02)02760-8","article-title":"Intensity-modulated radiotherapy versus conventional three-dimensional conformal radiotherapy for boost or salvage treatment of nasopharyngeal carcinoma","volume":"53","author":"Hsiung","year":"2002","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"2024050214503115300_b52","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.radonc.2012.08.013","article-title":"A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma","volume":"104","author":"Peng","year":"2012","journal-title":"Radiother Oncol"},{"key":"2024050214503115300_b53","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.7150\/jca.21009","article-title":"Patterns of failure and survival trends of 720 patients with stage I nasopharyngeal carcinoma diagnosed from 1990-2012: a large-scale retrospective cohort study","volume":"9","author":"Tang","year":"2018","journal-title":"J Cancer"},{"key":"2024050214503115300_b54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4103\/2278-330x.214578","article-title":"Epidemiology and outcomes of nasopharyngeal carcinoma: experience from a regional cancer center in southern India","volume":"6","author":"Haleshappa","year":"2017","journal-title":"South Asian J Cancer [Internet]"},{"key":"2024050214503115300_b55","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4103\/0019-509X.204762","article-title":"Outcomes in nasopharyngeal carcinoma: results from a nonendemic cohort","volume":"53","author":"Laskar","year":"2016","journal-title":"Indian J Cancer"},{"key":"2024050214503115300_b56","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.oraloncology.2016.10.011","article-title":"Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma","volume":"62","author":"Ou","year":"2016","journal-title":"Oral Oncol"},{"key":"2024050214503115300_b57","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00066-016-1052-2","article-title":"Nasopharyngeal carcinoma in a low incidence European area","volume":"192","author":"Tonoli","year":"2016","journal-title":"Strahlenther Onkol"},{"key":"2024050214503115300_b58","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/hed.24829","article-title":"Evolving trends in head and neck Cancer epidemiology: Ontario, Canada 1993-2010","volume":"39","author":"Mifsud","year":"2017","journal-title":"Head Neck"},{"key":"2024050214503115300_b59","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4143\/crt.2016.544","article-title":"A national study of survival trends and conditional survival in nasopharyngeal carcinoma: analysis of the national population-based surveillance epidemiology and end results registry","volume":"50","author":"Lv","year":"2018","journal-title":"Cancer Res Treat"},{"key":"2024050214503115300_b60","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(15)00055-0","article-title":"Nasopharyngeal carcinoma","volume":"387","author":"Chua","year":"2016","journal-title":"The Lancet"},{"key":"2024050214503115300_b61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdl320","article-title":"Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology","volume":"18","author":"S-H","year":"2007","journal-title":"Ann Oncol"},{"key":"2024050214503115300_b62","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00280-013-2196-8","article-title":"Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic\/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy","volume":"72","author":"Chen","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2024050214503115300_b63","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/hed.20161","article-title":"Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong nasopharyngeal carcinoma Study Group","volume":"27","author":"Yu","year":"2005","journal-title":"Head Neck"},{"key":"2024050214503115300_b64","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00405-016-4248-2","article-title":"A preliminary report on the role of endoscopic endonasal nasopharyngectomy in recurrent rT3 and RT4 nasopharyngeal carcinoma","volume":"274","author":"Wong","year":"2017","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2024050214503115300_b65","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s10147-017-1143-9","article-title":"Salvage endoscopic nasopharyngectomy for local recurrent or residual nasopharyngeal carcinoma: a 10-year experience","volume":"22","author":"Liu","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"2024050214503115300_b66","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/lary.25777","article-title":"Long-term outcomes of nasopharyngectomy using partial maxillectomy approach","volume":"126","author":"Ng","year":"2016","journal-title":"Laryngoscope"},{"key":"2024050214503115300_b67","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.radonc.2015.04.024","article-title":"Salvage endoscopic nasopharyngectomy is superior to intensity-modulated radiation therapy for local recurrence of selected T1-T3 nasopharyngeal carcinoma \u2013 a case-matched comparison","volume":"115","author":"You","year":"2015","journal-title":"Radiother Oncol"},{"key":"2024050214503115300_b68","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/hed.23880","article-title":"Long-term survival and late complications in intensity-modulated radiotherapy of locally recurrent T1 to T2 nasopharyngeal carcinoma","volume":"38","author":"Tian","year":"2016","journal-title":"Head Neck"},{"key":"2024050214503115300_b69","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/hed.24645","article-title":"Reirradiation with intensity-modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma","volume":"39","author":"Chan","year":"2017","journal-title":"Head Neck"},{"key":"2024050214503115300_b70","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1186\/s12885-018-5055-5","article-title":"Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma","volume":"18","author":"Kong","year":"2018","journal-title":"BMC Cancer"},{"key":"2024050214503115300_b71","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.7314\/APJCP.2014.15.8.3561","article-title":"Reirradiation with robotic stereotactic body radiotherapy for recurrent nasopharyngeal carcinoma","volume":"15","author":"Dizman","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"2024050214503115300_b72","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.7150\/jca.19078","article-title":"CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma","volume":"8","author":"Yan","year":"2017","journal-title":"J Cancer"},{"key":"2024050214503115300_b73","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1200\/JCO.2017.75.5165","article-title":"Prognostic model for stratification of radioresistant nasopharynx carcinoma to curative salvage radiotherapy","volume":"36","author":"Li","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024050214503115300_b74","volume-title":"7th International Congress on Innovative Approaches in Head and Neck Oncology","author":"Ruffier"},{"key":"2024050214503115300_b75","doi-asserted-by":"crossref","first-page":"774","DOI":"10.7150\/jca.14399","article-title":"Phase I\/II trial evaluating carbon ion radiotherapy for salvaging treatment of locally recurrent nasopharyngeal carcinoma","volume":"7","author":"Kong","year":"2016","journal-title":"J Cancer"},{"key":"2024050214503115300_b76","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.wjorl.2015.09.006","article-title":"Salvage surgery for nasopharyngeal cancer","volume":"1","author":"Tsang","year":"2015","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"2024050214503115300_b77","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2017.03.030","article-title":"Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma - How far have we achieved?","volume":"114","author":"Lee","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2024050214503115300_b78","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial","volume":"388","author":"Zhang","year":"2016","journal-title":"The Lancet"},{"key":"2024050214503115300_b79","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2018.05.14","article-title":"The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis","volume":"6","author":"Ma","year":"2018","journal-title":"Ann Transl Med"},{"key":"2024050214503115300_b80","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic phase 2 Consortium (NCI-9742","volume":"36","author":"Ma","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024050214503115300_b81","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed Death-Ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study","volume":"35","author":"Hsu","year":"2017","journal-title":"J Clin Oncol"},{"key":"2024050214503115300_b82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2017.10.016","article-title":"Delineation of the primary tumour clinical target volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines","volume":"126","author":"Gr\u00e9goire","year":"2018","journal-title":"Radiother Oncol"},{"key":"2024050214503115300_b83","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.radonc.2017.10.032","article-title":"International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma","volume":"126","author":"Lee","year":"2018","journal-title":"Radiother Oncol"},{"key":"2024050214503115300_b84","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.oraloncology.2014.01.017","article-title":"The impact of dosimetric inadequacy on treatment outcome of nasopharyngeal carcinoma with IMRT","volume":"50","author":"Ng","year":"2014","journal-title":"Oral Oncol"},{"key":"2024050214503115300_b85","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/(SICI)1097-0142(19980415)82:8<1449::AID-CNCR3>3.0.CO;2-4","article-title":"Epstein-Barr virus detection in nasopharyngeal tissues of patients with suspected nasopharyngeal carcinoma","volume":"82","author":"Tsai","year":"1998","journal-title":"Cancer"},{"key":"2024050214503115300_b86","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archotol.129.3.338","article-title":"Detection of Epstein-Barr virus in metastatic lymph nodes of patients with nasopharyngeal carcinoma and a primary unknown carcinoma","volume":"129","author":"Nakao","year":"2003","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2024050214503115300_b87","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/cncr.20099","article-title":"Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A\/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma","volume":"100","author":"Shao","year":"2004","journal-title":"Cancer"},{"key":"2024050214503115300_b88","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/cas.13296","article-title":"Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA","volume":"108","author":"Yao","year":"2017","journal-title":"Cancer Sci"},{"key":"2024050214503115300_b89","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1701717","article-title":"Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer","volume":"377","author":"Chan","year":"2017","journal-title":"N Engl J Med"},{"key":"2024050214503115300_b90","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"N Engl J Med"},{"key":"2024050214503115300_b91","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2018.77.7847","article-title":"Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial","volume":"36","author":"Chan","year":"2018","journal-title":"JCO"},{"issue":"Suppl 1","key":"2024050214503115300_b92","doi-asserted-by":"crossref","first-page":"e3912","DOI":"10.7717\/peerj.3912","article-title":"Clinical outcomes of residual or recurrent nasopharyngeal carcinoma treated with endoscopic nasopharyngectomy plus chemoradiotherapy or with chemoradiotherapy alone: a retrospective study","volume":"5","author":"Weng","year":"2017","journal-title":"PeerJ"},{"key":"2024050214503115300_b93","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijrobp.2017.09.038","article-title":"Facility volume and survival in nasopharyngeal carcinoma","volume":"100","author":"Yoshida","year":"2018","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"2024050214503115300_b94","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1200\/JCO.2014.56.5218","article-title":"Institutional clinical trial accrual volume and survival of patients with head and neck cancer","volume":"33","author":"Wuthrick","year":"2015","journal-title":"JCO"},{"key":"2024050214503115300_b95","article-title":"Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma","author":"Lee","year":"2019","journal-title":"Cancer"}],"container-title":["The British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/92\/1102\/20190068\/57378386\/bjr.20190068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/92\/1102\/20190068\/57378386\/bjr.20190068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T15:12:19Z","timestamp":1714662739000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/doi\/10.1259\/bjr.20190068\/7449229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,31]]},"references-count":95,"journal-issue":{"issue":"1102","published-online":{"date-parts":[[2019,5,31]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1259\/bjr.20190068","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10,1]]},"published":{"date-parts":[[2019,5,31]]},"article-number":"20190068"}}